Levetiracetam for Treatment of Non-psychotic and Non-depressive behavioural symptoms of dementia.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON23657

Enrollment

Registered

2006-08-08

Start date

2006-08-01

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

3 moths, prospective, open label trial

Interventions

500 mg Levetiracetam/day, maximum 1500 mg Levetiracetam/day.

Eligibility

Inclusion criteria

Inclusion criteria: 1. Ambulant patients with dementia, level Reisberg 4-6; 2. Informant available.; 3. 6 weeks stable treatment of dementia; anti-psychotics and anti-depressants.

Exclusion criteria

Exclusion criteria: 1. NPI item hallucinations, delusions and depression > ;1 2. Epilepsia; 3. Alcoholism; 4. DM or thyroid disease not under control.

Design outcomes

Primary

Measure	Time frame
Effect on week 4 and 13 compared to base-line on Behauvioral symptoms (NPI and CMAI), care-giver burden (CBI) and clinical impression (GCI).	—

Secondary

Measure	Time frame
Effect on week 4 and 13 compared to base-line on cognition (MMSE) and ADL (IDDD).	—

Contacts

Public ContactP.L.J. Dautzenberg

Jeroen Bosch Hospital, Department Geriatrics, P.O. Box 90153

p.dautzenberg@jbz.nl+31 (0)73 6998629

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)